These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3971652)

  • 1. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis.
    Lehmann CR; Heironimus JD; Collins CB; O'Neil TJ; Pierson WP; Crowe JT; Melikian AP; Wright GJ
    Clin Pharmacol Ther; 1985 Mar; 37(3):284-9. PubMed ID: 3971652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesis.
    Saller R; Hellenbrecht D; Briemann L; Hellstern A; Hess H; Mitrou P; Hodgson M; Achtert G; Brockmann P; Hausleiter HJ
    Clin Pharmacol Ther; 1985 Jan; 37(1):43-7. PubMed ID: 4038385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.
    Patel IH; Sugihara JG; Weinfeld RE; Wong EG; Siemsen AW; Berman SJ
    Antimicrob Agents Chemother; 1984 Apr; 25(4):438-42. PubMed ID: 6329080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capreomycin kinetics in renal impairment and clearance by hemodialysis.
    Lehmann CR; Garrett LE; Winn RE; Springberg PD; Vicks S; Porter DK; Pierson WP; Wolny JD; Brier GL; Black HR
    Am Rev Respir Dis; 1988 Nov; 138(5):1312-3. PubMed ID: 2462388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of single doses of metoclopramide in renal failure.
    Bateman DN; Gokal R; Dodd TR; Blain PG
    Eur J Clin Pharmacol; 1981; 19(6):437-41. PubMed ID: 7250177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefamandole in patients with renal impairment.
    Czerwinski AW; Pederson JA
    Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of cefsulodin in patients with renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Rev Infect Dis; 1984; 6 Suppl 3():S689-97. PubMed ID: 6571338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacology of cefamandole in patients with reduced renal function.
    Czerwinski AW; Pederson JA
    Scand J Infect Dis Suppl; 1980; suppl 25():45-8. PubMed ID: 6937951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics in renal disease.
    Levy G
    Am J Med; 1977 Apr; 62(4):461-5. PubMed ID: 851113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure.
    Wright MR; Axelson JE; Rurak DW; McErlane B; McMorland GH; Ongley RC; Tam YK; Price JD
    Br J Clin Pharmacol; 1988 Oct; 26(4):474-7. PubMed ID: 3190998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefsulodin kinetics in renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Kopferschmitt J; Spach MO; Grudet O; Lavillaureix J
    J Clin Pharmacol; 1979 Jul; 19(7):366-77. PubMed ID: 479381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metoclopramide decreases renal plasma flow.
    Israel R; O'Mara V; Austin B; Bellucci A; Meyer BR
    Clin Pharmacol Ther; 1986 Mar; 39(3):261-4. PubMed ID: 3948466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition and protein binding of batanopride and its metabolites in subjects with renal impairment.
    St Peter JV; Brady ME; Foote EF; Dandekar KA; Smaldone L; Pykkonen JL; Keane WF; Halstenson CE
    Eur J Clin Pharmacol; 1993; 45(1):59-63. PubMed ID: 8405031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
    Lavene D; Weiss YA; Safar ME; Loria Y; Agorus N; Georges D; Milliez PL
    J Clin Pharmacol; 1977; 17(8-9):501-8. PubMed ID: 893736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography.
    Graffner C; Lagerström PO; Lundborg P; Rönn O
    Br J Clin Pharmacol; 1979 Nov; 8(5):469-74. PubMed ID: 508553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.